Categories Earnings, Health Care

AngioDynamics misses Q3 earnings

AngioDynamics (NASDAQ: ANGO) posted third-quarter earnings on Tuesday before the regular trading hours. Net sales for the period increased 3% to $86.3 million, while adjusted net profit declined to $0.19 per share from $0.23 a year ago.

The market expected earnings of $0.22 per share on revenue of $88.65 million. Both the top line and bottom line missed the consensus.

An infographic on AngioDynamics' third quarter 2019 earnings results

US net sales in the quarter rose 3.9% to $68.3 million, while international sales edged down 0.3% to $18 million.

CEO CEO Jim Clemmer said, “While we had pockets of softness in our financial performance during the third quarter, our overall performance remains strong, and we are confident that we will achieve our full-year guidance. We saw strong growth contributions during the quarter from AngioVac and Solero, as well as from Fluid Management.”

The Latham, New York-based medical devices firm reiterated its FY 2019 guidance, continuing to expect net sales in the range of $354 to $359 million. Adjusted EPS is projected to be in the range of $0.82 to $0.86.

READ: LYFT AND SIX OTHER COMPANIES WENT PUBLIC IN MARCH. FULL LIST

ANGO ended its last trading session 9.4% higher on Monday. The stock has gained 46% in the trailing 52 weeks.

Last year, AngioDynamics announced that it would acquire privately held medical diagnostic and device company RadiaDyne. The latter designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

This deal added to AngioDynamics’ portfolio RadiaDyne’s early-stage, proprietary real-time radiation dose monitoring platform, and other market-leading oncology solutions.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top